<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168028">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730599</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-11-NG-0473</org_study_id>
    <nct_id>NCT01730599</nct_id>
  </id_info>
  <brief_title>A Longitudinal Study in Parkinson's Disease (PD) Patients</brief_title>
  <official_title>A Longitudinal 5 Years Follow up Study in Parkinson's Disease (PD) Patients Carriers of the LRRK2 Gene G2019S Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal study in patients with Parkinson's Disease (PD) carriers of a genetic
      mutation - substitution of gly with ser in position 2019 (G2019S) in the leucine-rich repeat
      kinase 2 (LRRK2) gene. The purpose of this study is to explore the association between
      genetic mutations in the known genes and their influence on disease manifestation over few
      years of follow up
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>change from baseline in updrs motor and total scores</measure>
    <time_frame>the participants will be followed for 5 years. the measurements will be taken evry 18 month.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>PD patients</arm_group_label>
    <description>PD patients carriers of the G2019S mutation in the LRRK2 gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neurological  exam</intervention_name>
    <description>motor and cognitive functions</description>
    <arm_group_label>PD patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PD patients carriers of the G2019S mutation in the LRRK2 gene
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  parkinson'd disease patients that already participated in a pasr cross sectional
             study

        Exclusion Criteria:

          -  subjects with cognitive decline by the parameters defined in  Diagnostic and
             Statistical Manual of Mental Disorders (DSM)- IV

          -  subjects with psychiatric disorder

          -  subjects unable to sign a consent form
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anat Mirelman, PhD</last_name>
    <phone>972-3-6973014</phone>
    <email>anatmi@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anat Mirelman, PhD</last_name>
      <phone>972-3-6973014</phone>
      <email>anatmi@tasmc.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 15, 2012</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
